Zacks Research Has Bullish Estimate for PLX FY2026 Earnings

Key Points

• Analysts at Zacks Research boosted Protalix's FY2026 EPS estimate to $0.17 from ($0.06), versus a consensus of $0.01, and project FY2027 EPS of $0.00.
• HC Wainwright reissued a Buy rating with a $12 target, and MarketBeat shows a consensus Buy rating with the same $12 target price.
• Shares opened at $2.14 with a market cap of about $172.4M, and several institutional investors have added to positions recently, leaving institutions owning roughly 16.53% of the stock.

Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) - Analysts at Zacks Research boosted their FY2026 earnings estimates for shares of Protalix BioTherapeutics in a research report issued on Wednesday, March 18th. Zacks Research analyst J. Vandermosten now anticipates that the company will post earnings per share of $0.17 for the year, up from their prior estimate of ($0.06). The consensus estimate for Protalix BioTherapeutics' current full-year earnings is $0.01 per share. Zacks Research also issued estimates for Protalix BioTherapeutics' FY2027 earnings at $0.00 EPS.

Separately, HC Wainwright reissued a "buy" rating and set a $12.00 target price on shares of Protalix BioTherapeutics in a research note on Thursday. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $12.00.

Protalix BioTherapeutics Stock Performance

NYSE:PLX opened at $2.14 on Monday. The stock has a market capitalization of $172.42 million, a PE ratio of -16.46 and a beta of -0.26. Protalix BioTherapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $3.19. The company has a fifty day moving average of $2.61 and a two-hundred day moving average of $2.21.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in Protalix BioTherapeutics by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 830,054 shares of the company's stock valued at $1,494,000 after purchasing an additional 10,277 shares in the last quarter. State Street Corp grew its holdings in shares of Protalix BioTherapeutics by 17.4% during the fourth quarter. State Street Corp now owns 585,261 shares of the company's stock worth $1,053,000 after buying an additional 86,714 shares in the last quarter. Stratos Wealth Partners LTD. raised its position in shares of Protalix BioTherapeutics by 42.9% in the third quarter. Stratos Wealth Partners LTD. now owns 500,000 shares of the company's stock valued at $1,110,000 after buying an additional 150,000 shares during the last quarter. Jane Street Group LLC raised its position in shares of Protalix BioTherapeutics by 159.0% in the first quarter. Jane Street Group LLC now owns 294,318 shares of the company's stock valued at $753,000 after buying an additional 180,702 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Protalix BioTherapeutics by 482.3% in the first quarter. Goldman Sachs Group Inc. now owns 289,461 shares of the company's stock worth $741,000 after buying an additional 239,751 shares in the last quarter. 16.53% of the stock is owned by institutional investors and hedge funds.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics NYSE: PLX is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix's core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company's first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.